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Abstract:
Background:
Clostridioides difficile  Infection (CDI) is an acute disease that needs a fast  proper treatment.  Unfortunately,  the diagnosis,  and above all  the
understanding of the results, remain arduous.
Objective:
This study analyzed routine and integrative results of all fecal samples from patients over time. Our aim was to understand the dynamics of CDI
infection and the meaning of “difficult to interpret” results, to make physicians better understand the various tools they can use.
Methods:
We  evaluated  routine  results  obtained  from  815  diarrheal  stools  with  Enzyme  Immunoassay  (EIA)  that  detects  C.  difficile  Glutamate
Dehydrogenase (GDH) antigen and toxin B. We also reanalyzed a part of samples using integrative tests: a Real-time polymerase chain reaction
(RT-PCR) for C. difficile toxin B gene (tcdB) and the automated immunoassay VIDAS C. difficile system for GDH and toxins A/B.
Results:
EIA GDH positivity increased through multiple testing over time, with a P value <0.001, depicting a sort of bacterial growth curve. Eighty-five
percent of GDH positive/toxin B negative, i.e., discrepant, samples PCR were tcdB positive, 61.5% of discrepant tcdB positive samples were
VIDAS toxins A/B positive, and 44.4% of GDH EIA negative stools were VIDAS GDH positive.
Conclusion:
The results confirmed the low sensitivity of the EIA system for C. difficile GDH and toxins, questioned the use of the latter for concluding any CDI
diagnostic algorithm, and led us to indicate the algorithm beginning with tcdB molecular research, and continuing in positive cases with VIDAS
CD GDH method, as the most effective for CDI.
Keywords: Clostridioides difficile infection, Diagnosis, Rapid enzyme immunoassay, Real-time polymerase chain reaction, Algorithm, TcdB
molecular researc.
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1. INTRODUCTION
Clostridioides difficile is a Gram-positive, spore forming,
strictly  anaerobic  bacterium.  It  is  the  leading  cause  of  the
principal antibiotic-associated diarrhea. In humans, C. difficile
Infection (CDI) is mediated by cytotoxic enzymes, i.e., toxin A
(TcdA), toxin B (TcdB), and, when present, by the binary toxin
(CDT), which can potentiate intestinal damage [1].
*  Address  correspondence  to  this  author  at  DISC,  Department  of  Surgical
Sciences  and  Integrated  Diagnostics,  University  of  Genoa,  10  Largo  Benzi,
16132, Italy; Tel: 39 3204207437; E-mail:piatti@unige.it
Given  the  feature  of  acute  infection,  CDI  needs  a  rapid
reliable  diagnosis,  which  avoids  empirical  therapies  and
consequent  further  dismicrobism,  responsible  for  most  cases
[2].  Diagnosis  of  CDI  is  performed  through  the  detection  of
toxins  in  stools.  The  Cell  Cytotoxicity  Neutralization  Assay
(CCNA)  primarily  reveals  the  presence  of  TcdB  through
cytopathic  effect,  whose  specificity  is  assured  precisely  by
neutralization. Given its high sensitivity and specificity, CCNA
is  recommended  as  a  reference  test.  Accomplishment  of  the
CCNA  procedure  is  long  and  burdensome,  thus,  for  routine
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diagnosis,  toxins  are  revealed  by  enzyme  immunoassays
(EIAs), which, though low in sensitivity, are fast and manage-
able [3].
Little toxin, sufficient to cause intestinal damage, such as
in  vitro  cytopathic  effect,  yet  not  sufficient  enough  to  be
always  detected  by  the  enzyme  immunoassay,  primarily
complicate CDI diagnosis [3]. For this reason, the efficacy of
the  EIA  system  has  been  increased  entrusting  it  with  the
detection  of  C.  difficile  glutamate  dehydrogenase  (GDH),
present  during  infection  in  large  quantities  [3]  but  endowed
with a  lower  specificity,  since GDH is  common to  toxigenic
and non-toxigenic strains [4, 5]. Secondly, in the human bowel,
C. difficile can be present in spore and vegetative forms, both
sharing tcdB, the gene codifying for TcdB and nowadays used
as a diagnostic target [6]. Thanks to the most recent works it is
now possible to overcome the old consequent debate, between
those authors who feared unrecognized infection and those who
feared over-diagnosis [7]. In 2016 and 2018, respectively, the
European and American Society of Infectious Diseases updated
diagnostic  guidance  documents  for  CDI,  giving  important
evidence about laboratory diagnosis [8, 9]. The most interes-
ting evidences are the inappropriateness of any test used as a
stand-alone,  the  evaluation  of  new  available  tests  and  their
possible employment in integrating the diagnostic systems and
creating a necessary algorithm.
In  our  opinion,  however,  clinicians  continue  to  have
difficulty  interpreting  those  diagnostic  results  which  are  not
fully consistent with each other, or are incomplete. Therefore,
the  aim of  this  work  was  to  discover  what  is  behind  the  so-
called  ‘difficult  to  interpret’  results  and  what  can  be  extra-
polated [4]. We report results obtained with C. difficile GDH
and toxin B EIA analyses on stools collected during 10 months
from  patients  suspected  of  suffering  from  CDI,  including
repeat samples. When possible, we employed integrative diag-
nostic  systems  to  reanalyze  samples  with  routine  discrepant
results.
2. MATERIALS AND METHODS
2.1. Patients and Setting
This  study  was  a  cohort  study  of  consecutive  patients
admitted to the San Martino Hospital in Genoa, Italy, and of
subjects  in  the  community  from  the  same  regional  area,
affected by diarrhea, from June 2013 to March 2014. Patient’s
stools were analyzed at the microbiology laboratory for TcdB
detection. All clinical specimens were collected and stored for
the  study  which  was  approved  by  the  Institutional  Ethics
Committee of  San Martino University Hospital  (n.  reg.  CEA
13/11-Progetto  istMicro1/2011).  We  considered  the  total
number of patients and analyses, including those repeated for
single  subjects  and  changes  of  results  concerning  single
patients  over  the  time.
2.2. Microbiological Methods
Diarrheic stools were routinely analyzed for the presence
of  C.  difficile  GDH  and  C.  difficile  toxin  B  with  a  Rapid
Membrane  EIA,  C.  difficile  Quik  Chek  Complete  (Techlab
Inc.) within 1 hour from arrival at the laboratory and according
to  the  manufacturer's  instructions.  Depending  on  the
availability of fecal material, GDH positive, toxin B negative
samples, the previously called “discrepant samples” [4], were
further  analyzed  by  nucleic  acid  amplification  test  for  C.
difficile toxin B gene (tcdB) and the more sensitive automated
immunoassay VIDAS C. difficile Tox A/B (BioMerieux) [10].
For the detection of tcdB,  bacterial DNA was extracted from
stools with the automated device QIAcube (QIAGEN). Using
the  extracted  DNA,  we  performed  Real-Time  Polymerase
Chain Reaction (RT-PCR) using RealCycler CDIF (Progenie
Molecular),  suitable  to  detect  the  tcdB  gene  directly  from
stools,  following  the  manufacturer’s  instructions.  Fifty-three
EIA GDH negative/toxin B negative samples were reanalyzed
with  the  automated  immunoassay  VIDAS  C.  difficile  GDH
(BioMerieux).
2.3. Statistical Methods
The  occurrence  of  the  three  possible  outcomes  from  the
assay matching GDH and toxin B (positive/positive, negative
/negative, positive/negative) with respect to tests repeated over
time  was  tested  by  means  of  the  multinomial  logistic  model
[11]. This model performed the ratio between the percentage of
positive  results  (GDH  positive/toxin  B  positive  and  GDH
positive/toxin B negative) for the additional samples over time
with respect to the first sample, thus estimating Relative Risks
(RRs).  These  RRs  were  then  compared  with  the  analogous
relative  risks  estimated  for  the  double  negative  GDH
negative/toxin B negative outcome, thus obtaining the Relative
Risks  Ratio  (RRR).  The  standard  errors  estimated  from  the
multinomial model were adjusted by the clustering effect due
to the repeated observations on the same subject.  The Kappa
test  was  performed  to  evaluate  the  agreement  between  the
different assays. To avoid the influence of repeated measures,
the  Kappa  test  was  applied  to  the  sum  of  positivity  of  each
assay [12].
3. RESULTS
3.1.  Patients,  Stools  and  Analyses  with  the  Routine  EIA
System
Over the study period, we routinely analyzed 815 diarrheal
stools from 502 subjects with EIA systems. Fig. (1) shows total
patients, disease onset according to EIA C. difficile GDH/ toxin
B  results,  total  stools  and  the  relevant  EIA  results,  grouped
according  to  single  or  multiple  stools.  We  did  not  show
epidemiological  data  concerning  patients  as  they  were  not
relevant to our analysis. Table 1 shows that, in addition to the
334 (66.5%) patients with a single analysis, 168 (33.5%) (data
not  shown)  patients  with  multiple  analyses,  i.e.,  72  (14.4%)
patients with multiple analyses always giving the same result,
positive,  negative  or  discrepant,  and  96  (19.1%)  giving
different results over time. Sixty of them (11.9%) had positive
onset, 19 (3.8%) had negative onset and 17 (3.4%) discrepant
(data not shown).
Table 2 reports the results of the EIA system for GDH and
toxin B, stratified by single or multiple stools. Observing the
row of percentages, it is clear that the frequency of positivity
increases through multiple testing over time. The multinomial
logistic model was applied to test this hypothesis. This model
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shows  that  the  probability  of  finding  a  positive  result  signi-
ficantly increases by performing up to two or three replicates,
at  least  for  +/–  (RRR  =  2.36;  95%CI  =  1.54-3.60  and
RRR=3.74; 95%CI = 2.07-6.76 respectively; P <0.001) while
for +/+ the result is not significant (P = 0.206) (Table 3).
Fig (1).  Flow chart  of patients and the relevant laboratory results of
Clostridium difficile infections in stool samples by routine EIA system.
Table  1.  Patient  cohort  according  to  the  number  of
specimens collected and according the results of C. difficile
GDH/ toxin B EIA in fecal specimens.
Specimen/s Results PatientsNumber
%
single +/+ 50 9.9
single -/- 239 47.6
single +/- 45 9.0
total single 334 66.5
multiple always +/+ 14 2.8
multiple always -/- 52 10.4
multiple always +/- 6 1.2
total multiple always 72 14.4
multiple variable 96 19.1
Total 502 100
+/+, CD GDH positive/toxin B positive; -/-, CD GDH negative/toxin B negative,
+/-, CD GDH positive/toxin B negative.
Table 2. Results of C. difficile GDH/toxin B EIA, stratified





Multiple Test – Total N.
Yes No. Yes % No No. No %
+ + 149 74.87 50 25.13 199
- - 224 48.38 239 51.6 463
+ - 108 70.59 45 29.41 153
Total stools 481 59.02 334 40.98 815
+, positive; -, negative.
3.2. Fecal Samples Analyzed with Integrative Tests
Table 4 shows, for descriptive purposes only, the relative
frequencies of the EIA GDH positive/toxin B negative and EIA
GDH  negative/toxin  B  negative  stools,  which  were  positive
using the integrative systems targeting tdB  or  the  VIDAS C.
difficile toxin A/B and the VIDAS C. difficile GDH tests, and
the  provenance  according  to  patients  and  single  or  multiple
samples.  Fig.  (2)  describes  the  total  positive  results  for  CDI
according to  the stool  sample during the time,  obtained with
routine  analyses  and  with  the  integrative  tests  utilized  and
shown in Table 4.
Table 3. Increase in frequency of C. difficile GDH/toxin B
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Table 4.  Results of C. difficile  GDH/toxin B EIA analyses



















– 44 60 variable positive negative 50 10
– 5 8 always
+/-
positive negative 8 (85.3)* 0
(14.7)*
– 23 32 variable negative negative 13 (40.6) 19
(59.4)
Total – 100 – – – 71 (71) 29 (29)





– 27 30 variable positive negative 17 13
– 2 3 always
+/-
positive negative 2 1
– 6 6 single
+/-
positive negative 5 1
Total 35 39 – – – 24 (61.5) 15
(38.5)






– 36 54 variable negative negative 24 (44.4) 30
(55.6)
Percentage  values  relative  to  the  stools  column are  in  brackets.  *,  percentage
value refers to the sum of lines 1 and 2.
3.2.1. Samples analyzed with PCR for tcdB
We selected 100 fecal samples, 68 EIA discrepant and 32
double negative, where to search for tcdB with the RealCycler
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were  tcdB  positive,  while  tcdB  positivity  decreased  to  71%
among  all  one-hundred  selected  samples.  In  fact,  the  tcdB
positivity percentage among the 32 negative EIA samples was
40.6% and attributed greater sensitivity to PCR for toxin gene
compared  to  the  EIA  system  for  GDH.  All  eight  discrepant
stools  of  patients  who had always given the same discrepant
result  were  tcdB  positive.  This  is  noteworthy  because,
assuming that the individual patient had the same intestinal C.
difficile strain in a short time, it leads us to consider the role of
genetic  groups,  hyper  virulent  or  not,  in  the  genesis  of
discrepant  results  [3].  Thirty-two  stools  were  EIA  negative
from  23  patients  giving  variable  results  over  time,  half  of
which  also  had  discrepant  EIA  results  and  belonged  to  the
aforementioned  group  of  44  subjects.  Three  EIA  negative
subjects  had  both  positive  and  negative  tcdB.  Compared  to
GDH  EIA  tests,  tcdB  assay  shows  an  agreement,  i.e.,  the
relative frequency when the two methods are jointly positive or
negative,  of  69.4%.  Applying  the  Kappa  test  to  check  the
repeatability  between  the  two  methods,  the  hypothesis  of  a
random agreement, estimated to be 42.1%, was rejected with a
P <0.001.
3.2.2.  Samples  analyzed  with  the  automated  immunoassay
VIDAS C. difficile Tox A/B
We selected 39 toxin B EIA negative samples where tcdB
and GDH EIA positivity ensured, respectively, the presence of
toxigenic  strains  and  germinating  conditions,  to  search  for
toxin  B  with  a  test  more  sensitive  than  EIA,  the  VIDAS
method [10]. Positive VIDAS toxin B stools were globally 24
out of 39. Out of the 24 VIDAS toxins positive stools, only 9
were  onset  samples,  while  15  from  13  patients  were  repeats
(data not shown). The observed agreement with GDH is 60.0%,
quite different from the random one of 46.2%, thus the random
agreement  hypothesis  was  rejected  by  the  Kappa  test  (P
<0.001).
3.2.3.  Samples  analyzed  with  the  automated  immu-noassay
VIDAS C. difficile GDH
We  analyzed  54  EIA  GDH  negative/toxin  B  negative
samples  with  the  VIDAS  C.  difficile  GDH  test,  in  order  to
confirm the greater sensitivity of this system on the GDH target
with respect to EIA. We selected these samples as likely to be
positive, in that coming from 36 patients with variable results.
We obtained 24 VIDAS C. difficile GDH positive results and
30  negative.  Out  of  24  VIDAS  GDH  positive  stools,  only  5
were onset  samples,  while  19 from 17 patients  were repeats,
and 11 preempted those obtained with the EIA system (data not
shown). Since the observed and the expected agreement with
EIA  GDH  were  only  slightly  different  (50.0  and  47.2
respectively)  the  Kappa  test  suggested  that  the  concordance
between the two assays was not significant (P = 0.138). Out of
24  EIA  GDH  negative  stools  retested  with  both  VIDAS  for
GDH  and  PCR  for  tcdB,  15  were  GDH  positive  and  9  were
negative,  while  12  were  tcdB  positive  and  12  were  negative
(data not shown).
Fig (2).  Total positive results for Clostridium difficile  infection deriving from onset and repeat analyses over time performed with routine EIA























































 1st Sample 2nd Sample 3rd Sample 4th Sample or more
CD GDH (502 / 168 /72 / 73)
CD toxin B (502 / 168 / 72/ 73)
tcdB (18 / 33 / 26 / 23)
CD GDH VIDAS (8 / 15 / 14 / 17)
CD toxin B VIDAS (13 / 14 / 6 / 6)
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4. DISCUSSION
In the last years, a better knowledge of C. difficile infection
clarified  some  misleading  points,  which  previously  had
increased  the  intrinsic  limits  of  diagnostic  tools.  The  main
achievement is represented by the fact that over diagnosis is no
longer contested with evidence of cases of underdiagnoses, and
vice  versa  [13  -  16].  Actually,  the  diagnostic  guidance
recommendation  for  using  a  diagnostic  algorithm  just  arises
from awareness that various pathogenic frameworks, due to the
same  bacterium,  are  possibly  present  behind  various
unsatisfying diagnoses or fragments of results, and cannot be
distinguished by a single test alone [8, 9]. Nevertheless, CDI
diagnosis  remains  complex,  more than that  of  most  bacterial
infections  [3].  In  our  opinion,  some  viewpoints  do  remain
unconvincing, such as the idea of possible toxins’ degradation,
and  prevent  clinicians  from  having  a  vision  clear  enough  to
extrapolate what is  best  for  the individual  patient  from diag-
nostic results.
We  evaluated  the  first  and  the  additional  analyses  of  all
subjects  suspected  of  being  affected  by  CDI,  to  know  the
dynamic of the infection, to select samples for analyses with
integrative tests and to frame the relevant results in the right
context.
One  third  of  our  cohort  was  composed  of  subjects  who
gave subsequent samples over time. More than one third of the
stools  were  repeats.  This  aspect  primarily  shows  a  lack  of
confidence  in  the  tests  for  CDI  detection,  which  led  to  the
disregard,  in  our  institution,  of  the  recommendation  not  to
repeat tests [8].
Data from routine analyses show that, by performing up to
three  or  four  new  EIA  analyses,  the  probability  of  detecting
GDH positivity  significantly  increases,  while  that  of  finding
toxin  B  positivity  increases  less  clearly.  In  the  past,  the
possible benefit  deriving from repeated testing using CCNA,
PCR for tcdB and the EIA system for toxins was excluded [17 -
19]. It is possible that the most sensitive analyses, as well as
the  least  sensitive  one,  were  equally  indifferent  to  possible
changes in bacterial amount during infection. Different to the
EIA  GDH  performance  observed  here,  CCNA  and  PCR  for
tcdB may not require peaks in quantity to detect their targets,
and  EIA  toxin  B  sensitivity  may  never  reach  the  detection
threshold.
Previous studies showed that C. difficile bacterial load in
infection,  expressed  as  CFU/g  or  tcdB  DNA  copies/mL,
positively correlates with stools positive for tcdB and even for
toxins’ products detected with the EIA system [20, 21]. Other
works  reported  the  same  correlation  indirectly,  through  the
degree of severity of the cases [16, 22, 23]. Therefore, results
varying  over  time  within  single  subjects  could  indirectly
indicate variable fecal loads of C. difficile, that, probably as in
other  infections,  follows  a  sort  of  growth  curve.  We  did  not
consider  the  gain  in  positivity  of  the  repeats  obtained  with
integrative  tests,  even  if  apparently  evident,  in  that  we
performed  a  precise  selection  of  stools  eligible  for  further
analyses,  distorting  our  epidemiology.
We  absolutely  do  not  propose  additional  samples  to
achieve a diagnostic certainty, in that this would contradict the
need for  fast  results.  Moreover,  EIA GDH multiple  analyses
would not be exhaustive, yielding a gain in positivity resulting
from the intermediate sensitivity, while recovery of positivity
for EIA toxins would not be significant. We analyzed results
from repetitions just to confirm the bacterial dynamics we had
hypothesized,  which  in  turn  is  partly  responsible  for  the
complexity of CDI diagnosis, and which, in our opinion, must
be taken into account.
Out  of  the  thirty-nine  EIA  discrepant/tcdB  positive
samples,  which  indicated  the  presence  of  vegetative  and
toxigenic  strains,  twenty-four  were  positive  for  C.  difficile
toxin B with the VIDAS ToxinA/B test. Given the low quantity
of many feces, these results are partial, when compared to the
total  number.  However,  we can assert  that,  in these samples,
CD  toxin  was  present,  detectable  with  a  test  more  sensitive
than  the  routine  one,  and  not  degraded,  as  instead  emerged
from other works [21, 24 - 26]. In our opinion, toxin quantity
under the detection threshold of the EIA, and more rarely under
the  threshold  of  VIDAS  system,  whose  higher  sensitivity
compared to EIA is also confirmed on GDH target, is the most
plausible explanation for GDH positive, toxins negative, tcdB
positive  results.  The  toxins’  instability  had  already  been
considered responsible for the greater sensitivity of Toxigenic
Cultures  (TC)  compared  to  CCNA [7].  It  is  now ascertained
that the greater sensitivity of TC, compared to detection toxin
products’ detection, is illusory and due to the low specificity of
the method that,  like PCR for  tcdB,  also detects  spore forms
[16].
Our results, as well as those of authors here cited, lead us
to  disagree  with  the  specific  proposal  to  follow  with  EIA
systems for CD toxins the positivity of CDI algorithms started
with EIA GDH or with PCR for tcdB  [8, 9, 27]. In fact, EIA
systems  for  toxins  detection  are  not  sensitive  enough  to
conclude  the  algorithm  in  case  of  its  own  negativity.
Furthermore,  given  the  current  availability  of  EIA  tests
complete  for  both  GDH and toxins  A/B,  the  choice  of  GDH
alone as the first step of the algorithm is not clear, and testing
for toxins in sequence would be a step backwards. Companies
improved EIA systems for CDI with GDH to recover samples
that would be negative when evaluated for toxins alone, and to
address the search for tcdB only where it is worthwhile. That is
where GDH indicates CD germination but the toxins’ products
are  not  detected.  However,  the  present  data  on  the  greater
sensitivity  of  VIDAS  and  on  its  ability  to  anticipate  GDH
detec-tion compared to EIA, although few, show the possibility
that EIA does not detect a GDH positivity that would otherwise
be detectable. Since the VIDAS system is not manageable as
EIA,  the  same  VIDAS for  GDH is  not  suitable  as  a  starting
point  for  a  routine  algorithm.  Moreover,  here,  we  confirmed
the higher sensitivity of PCR for tcdB compared to both EIA
and  VIDAS  for  GDH,  due  in  part  to  the  molecular  method
itself, which is indeed amplification, and partly to the different
target [3].
VIDAS C. difficile  GDH. On top of  the  columns are  the
absolute numbers of positive results. The frame containing the
legend of tests utilized, shows the total number of 1st samples
(onset assay) and those of the 2nd, 3rd, and 4th samples (repeat
assays), in brackets.
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The bacterial  dynamic we observed by following a  large
number  of  subjects  over  time,  and  the  variables  it  can
contribute  to  create,  confirm  the  great  complexity  of  the
disease. This imposes, in turn, an unequivocal diagnostics, only
achievable through an algorithm. We think that, in the current
state of technology, the beginning of CDI algorithm should be
entrusted  to  the  search  for  tcdB,  nowadays  manageable.
Positive  cases,  in  which  it  is  worth  continuing  the
investigation,  in  small  quantities,  should  be  followed  by
VIDAS GDH, to exclude spore forms. In fact, in our opinion, it
is  preferable  to  begin  any  diagnostic  process  with  the  more
sensitive method, especially when it  is possible to correct its
poor specificity, rather than underestimating a disease.
CONCLUSION
The above mentioned algorithm is quite feasible with the
current tools, although these are not available in all diagnostic
laboratories.  Anyway,  even  incomplete  results,  and  those
somewhat discordant, can be correctly interpreted and utilized
by physicians. Faecal CD GDH alone, not supported by toxins
or tcdB positivity, not found or not searched, represents the risk
of  germination  for  any  new  toxigenic  strains.  The  tcdB
positivity  alone,  not  supported  by  the  presence  of  GHD  and
toxins’ products, not found or not searched, indicates the faecal
presence of C. difficile  spore forms that  can germinate when
the environment is  suitable,  condition underlying CDI recur-
rence [13, 28]. The algorithm itself must be clearly interpreted
as a diagnostic path that distinguishes the low amount of toxin
from the non-toxigenic C. difficile, and germination or not of
toxigenic strains.
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